GH secretion status in myotonic dystrophy.
Frequent endocrine alterations and abnormal growth hormone (GH) secretion have been reported in myotonic dystrophy (MD). To evaluate GH secretion status in MD, GH response to 100 micrograms of growth hormone releasing hormone (GHRH) with or without pyridostigmine pretreatment and its relation with insulin-induced hypoglycemia was investigated in MD patients and compared with normal controls. The mean peak plasma GH response to GHRH was 27.8 +/- 19.2 micrograms/l normal subjects and 11.4 +/- 8.7 micrograms/l in MD patients. In five of seven patients GH reached a mean peak of 12.6 +/- 4.2 micrograms/l after insulin-induced hypoglycemia, compared with 5 +/- 2.8 micrograms/l after GHRH. Conversely, in two patients GH reached a peak of 16.1 and 32 micrograms/l after GHRH, and only 2.5 and 5.3, respectively, after hypoglycemia. Pretreatment with pyridostigmine in nine patients tested potentiated GHRH-induced GH release with a peak of 17.6 +/- 12.5 micrograms/l, compared with 10.05 +/- 6.7 micrograms/l after GHRH alone; IGF-I levels were normal in all patients.
Endocrine Department, Hospital de Bellvitge, Universidad de Barcelona, Spain.
J M
JM
Gómez-Sáez
J M
JM
Fernández-Real
M A
MA
Navarro
J A
JA
Martínez-Matos
J
J
Soler
D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D008297:Male; D008875:Middle Aged; D009223:Myotonic Dystrophy / Q000097:blood* / Q000235:genetics; D011863:Radioimmunoassay; D012016:Reference Values
D001786:Blood Glucose; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone